781 related articles for article (PubMed ID: 17665460)
1. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
2. Determinants of morbidity and mortality of systemic sclerosis in Canada.
Al-Dhaher FF; Pope JE; Ouimet JM
Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
[TBL] [Abstract][Full Text] [Related]
3. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
[TBL] [Abstract][Full Text] [Related]
4. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.
Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Muro Y; Ogawa F; Sasaki T; Takahashi H; Tanaka S; Takehara K; Sato S
Rheumatology (Oxford); 2012 Jan; 51(1):129-33. PubMed ID: 22072085
[TBL] [Abstract][Full Text] [Related]
5. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.
Dziadzio M; Smith RE; Abraham DJ; Black CM; Denton CP
Rheumatology (Oxford); 2005 Dec; 44(12):1518-24. PubMed ID: 16159952
[TBL] [Abstract][Full Text] [Related]
7. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
9. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
[TBL] [Abstract][Full Text] [Related]
10. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
11. Increased serum soluble CD40 levels in patients with systemic sclerosis.
Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
[TBL] [Abstract][Full Text] [Related]
12. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody.
Sacks DG; Okano Y; Steen VD; Curtiss E; Shapiro LS; Medsger TA
J Rheumatol; 1996 Apr; 23(4):639-42. PubMed ID: 8730118
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Simon D; Czömpöly T; Berki T; Minier T; Peti A; Tóth E; Czirják L; Németh P
Int Immunol; 2009 Apr; 21(4):415-22. PubMed ID: 19211583
[TBL] [Abstract][Full Text] [Related]
14. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
[TBL] [Abstract][Full Text] [Related]
15. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Kuwana M; Kaburaki J; Mimori T; Kawakami Y; Tojo T
Arthritis Rheum; 2000 May; 43(5):1074-84. PubMed ID: 10817562
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
[TBL] [Abstract][Full Text] [Related]
18. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
19. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
[TBL] [Abstract][Full Text] [Related]
20. Renal function is mostly preserved in patients with systemic sclerosis.
Scheja A; Bartosik I; Wuttge DM; Hesselstrand R
Scand J Rheumatol; 2009; 38(4):295-8. PubMed ID: 19214870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
